Postmenopausal Women With Osteoporosis Clinical Trial
Official title:
A Multicenter, International, Randomized, Double-blind, Alendronate-controlled Study to Determine the Efficacy and Safety of Romosozumab in the Treatment of Postmenopausal Women With Osteoporosis
The purpose of this study is to determine if treatment is effective in preventing fractures in women with postmenopausal osteoporosis.
In this trial, women were randomly assigned in a 1:1 ratio to receive monthly subcutaneous romosozumab or weekly oral alendronate for 12 months. Randomization was stratified according to age (<75 vs. ≥75 years). After completion of the double-blind treatment period, all the participants were to receive open-label weekly oral alendronate until the end of the trial, with blinding to the initial treatment assignment maintained. The primary analysis was performed when clinical fracture events had been confirmed in at least 330 participants and all the participants had completed the month 24 visit. The study was to continue in an event-driven manner until at least 440 participants experienced a nonvertebral fracture or if the superiority of romosozumab was proven for nonvertebral fractures at the primary analysis. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT01249261 -
Effect of Stopping Risedronate After Long Term Treatment on Bone Turnover
|
Phase 3 | |
| Active, not recruiting |
NCT05345691 -
Comparison of Efficacy, Pharmacodynamics, Safety, and Immunogenicity Between Bmab 1000 and Prolia® in Postmenopausal Women With Osteoporosis
|
Phase 3 | |
| Active, not recruiting |
NCT05338086 -
A Study to Compare Efficacy, Pharmacokinetics, Pharmacodynamics, Safety and Immunogenicity of MB09 [Proposed Denosumab Biosimilar] to Prolia® [EU-sourced] in Postmenopausal Osteoporosis (SIMBA Study)
|
Phase 3 | |
| Completed |
NCT04757376 -
A Phase 3 Study to Compare Between CT-P41 and US-licensed Prolia in Postmenopausal Women With Osteoporosis
|
Phase 3 | |
| Completed |
NCT03974100 -
Study Investigating PK, PD, Efficacy, Safety, and Immunogenicity of Biosimilar Denosumab (GP2411) in Patients With Postmenopausal Osteoporosis
|
Phase 3 | |
| Completed |
NCT01581320 -
Phase III Clinical Trial of DP-R206 and Bonvia In Postmenopausal Women With Osteoporosis
|
Phase 3 |